Retatrutide Research Peptide — 1mg Lyophilized
Retatrutide (LY3437943) is a novel synthetic triagonist peptide that simultaneously activates three key metabolic receptors: GLP-1 receptor (GLP-1R), GIP receptor (GIPR), and glucagon receptor (GCGR). Developed by Eli Lilly, Retatrutide is being studied in published clinical trials as a potential metabolic disorder treatment candidate.
Research applications include in vitro receptor pharmacology studies, comparative agonist activity profiling for GLP-1/GIP/glucagon receptors, adipocyte biology research, and pancreatic beta-cell function studies. Its triple receptor activity makes it a unique tool for dissecting incretin/glucagon co-signaling pathways.
Research Specifications
- Molecular Weight: ~4,700 Da
- Purity: ≥98% (HPLC-MS)
- Storage: -20°C
⚠️ Research Use Only. Not for human use. Investigational compound only.
